# SHR-1701 Combined with SHR2554 and BP102 for MCRC

> **NCT06679673** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 20 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** SHR-1701
- **DRUG:** BP102
- **DRUG:** SHR2554

## Key facts

- **NCT ID:** NCT06679673
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06679673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06679673, "SHR-1701 Combined with SHR2554 and BP102 for MCRC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06679673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*